— Know what they know.
/
Not Investment Advice

PFE

NYSE · USD
Pfizer Inc.
Healthcare · Drug Manufacturers - General
CEO Albert Bourla Employees 75,000 R&D / revenue 19.1%
Last price
$29.58+0.48%last session
Market cap
$168.6B
P/E (TTM)
39.1x
From 52w high
−1.0%
From 52w low
+25.2%
1-year return
+24.2%
RSI 14 · vs SMA200
69.7 · +11.6%
IS score
46.1/ 100
Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.
Download full factsheet (PDF)

One year, rebased to 100

PFE   SPY   XLV (sector ETF) · weekly closes
100110120Jan 26Apr 26Jul 26Oct 26PFE 124XLV 124SPY 116

Score DNA

Each bar is a 0-100 score within the scored universe
45
Profitability
20
Growth
49
Value
55
Momentum
50
Risk (safety)
73
Quality
43
Balance sheet
71
Earnings quality

Flags

Strengths
✓ FCF yield 5%+✓ Insider buying✓ Congress buying
Warnings
None of the computed warning flags fires for PFE (Altman, Beneish, accruals, FCF, dilution).
Observations
Moat model: Narrow, Efficient ScalePiotroski 7 / 9Altman Z 2.0Beta 0.304 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.
INSForm 4 · 180 days
Insider open-market buys
3
$2.96M bought
No Form 144 notices in 12 months
CONGSTOCK Act · 180 days
Congressional purchases
3
Last disclosed purchase 2026-09-25
Members disclose in ranges, 30-45 days after the trade
13F13F · quarter to 2026-06-30
Net change in institutional holders
−119
153 new holders, 233 closed
2,849 filers hold 67.8% · 1,167 added, 1,227 trimmed
ETFETF holdings · 30 days
Net funds accumulating
+237
1,403 funds adding shares
1,166 funds trimming · counts of funds, not dollars
DARKFINRA · daily
Short-sale share of off-exchange volume
42.8%
20-day avg 46.4%, 50-day avg 42.6%
Latest 3.6 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.
Income statement
Revenue$62.6B
Revenue growth YoY−1.6%
Gross margin70.3%
Operating income$15.4B
Operating margin24.7%
Net income$7.8B
Net margin12.4%
EPS (diluted)$1.36
Cash flow
Operating cash flow$11.7B
Capital expenditure$2.6B
Free cash flow$9.1B
FCF conversion (FCF / OCF)77.5%
Stock-based compensation$0
FCF less SBC$9.1B
Buybacks$0
Dividends$9.8B
Balance sheet & returns
Cash & short-term investments$13.6B
Total debt$65.1B
Net debt$51.5B
Shareholders' equity$86.8B
Goodwill & intangibles$125.0B
Debt / equity0.74
ROE (TTM)4.9%
ROIC (TTM)9.3%
Operating margin by fiscal year
26.9%FY202137.9%FY20228.0%FY202326.9%FY202424.7%FY2025
Revenue $81.3B (FY2021) to $62.6B (FY2025), a -6.3% CAGR.

Valuation

P/E (TTM)39.1x
EV / EBITDA17.1x
Price / sales2.65x
Price / FCF15.3x
FCF yield6.52%
Buyback yield0.00%
SBC / revenue1.5%
Price / book1.98x
Forward P/E FY202610.0x
Forward P/E FY202710.2x
Forward P/E FY202811.9x
Forward multiples divide today's price by Street EPS estimates. Street mean target $30.50 across 4 analysts last quarter is theirs, not ours.

PFE vs industry median

40 companies in Drug Manufacturers - General
Gross margin 71.3% 72.4% Operating margin 25.1% 20.1% Net margin 6.8% 12.7% ROIC 9.3% 16.2%
PFE (TTM)Industry median Asset turnover 0.32 vs industry 0.54 · financial leverage 2.36

Earnings delivery

Next report 2026-11-03 · consensus EPS $0.73
100%
beat rate, 12 of 12 quarters
+36.0%
median EPS surprise
12
longest beat streak
+47+153+59+31+73+34+38+34+37+16+4+13
EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2023-10-31 to 2026-08-04. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above
CompanyMkt capP/EROENet marginRev growth12m return
PFE Pfizer Inc. $168.6B39.1x4.9%6.8%−1.6% +24.2%
GILD Gilead Sciences, Inc. $193.7Bn/m-20.6%—+5.5% +33.4%
BMY Bristol-Myers Squibb Company $122.1B13.2x46.7%25.6%+3.1% +43.8%
AMGN Amgen Inc. $233.8B26.7x91.5%23.6%+9.2% +50.3%
AZN AstraZeneca PLC $256.5B24.7x22.0%16.3%+8.6% −1.5%
NVS Novartis AG $286.3B22.9x30.6%22.7%+0.8% —
MRK Merck & Co., Inc. $360.1B115.8x7.0%-8.0%+4.5% —
ABBV AbbVie Inc. $504.4B80.4x-206.4%21.3%+10.4% —
12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-08-04Earnings Release; Exhibits
2026-06-18Officer/Director Change; Exhibits
2026-06-18Regulation FD
2026-05-05Earnings Release; Exhibits
2026-04-27Shareholder Vote
2026-02-03Results of Operations and Financial Condition; Financial Statements and Exhibits

Context

Shares outstanding5,699,670,000
Free float99.9%
Institutional ownership67.8%
Beta0.30
Dividend yield5.81%
Last dividend$0.43 on 2026-11-06
50 / 200-day average$27.90 / $26.54
Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where PFE sits among 12 scored companies in Drug Manufacturers - General (0 = lowest value, 100 = highest). It is a position, not a grade.
ValuationProfitability (TTM)Returns on capitalGrowthMargin history & stabilityLiquidity (latest quarter)Leverage & solvency (latest quarter)EfficiencyCash flow & earnings qualityDividends & buybacksScores & forensic checksPer shareSize (TTM)

Valuation

MeasurePFEIndustry medianIndustry percentileSector median
P/E (TTM) 38.9x 29.3x
60th		 27.6x
PEG (P/E ÷ 3-yr EPS CAGR) —
Price / sales 2.6x 5.3x
18th		 3.7x
Price / book 2.0x 6.9x
10th		 3.6x
Price / tangible book —
Price / free cash flow 15.3x 20.3x
36th		 21.2x
Price / operating cash flow 12.6x 16.8x
27th		 17.1x
Enterprise value $220.1B $280.5B
36th		 $2.5B
EV / sales 3.5x 6.0x
18th		 3.8x
EV / EBITDA 16.9x 18.0x
45th		 16.2x
EV / EBIT 31.9x 24.8x
60th		 23.0x
EV / free cash flow 20.0x 23.7x
27th		 24.6x
Earnings yield 2.6% 3.0%
45th		 -0.3%
FCF yield 6.5% 5.0%
64th		 1.7%
Operating cash flow yield 7.9% 6.0%
73rd		 2.9%
Graham number (per share) $15.99 $63.36
11th		 $26.70

Profitability (TTM)

MeasurePFEIndustry medianIndustry percentileSector median
Gross margin 71.3% 72.1%
36th		 65.1%
EBITDA margin 20.5% 32.8%
9th		 6.6%
Operating margin 25.1% 25.2%
45th		 3.5%
EBIT margin 10.8% 22.0%
9th		 2.4%
Net margin 6.8% 13.4%
27th		 0.3%
NOPAT margin 26.1% 20.5%
82nd		 2.7%
FCF margin 17.2% 24.7%
18th		 4.3%
Operating cash flow margin 21.0% 29.5%
9th		 7.1%
R&D / revenue 20.1% 20.0%
64th		 12.4%
SG&A / revenue 20.9% 22.0%
36th		 37.9%
Stock comp / revenue 1.1% 1.1%
64th		 4.5%
Effective tax rate -3.9% 19.2%
0th		 21.0%

Returns on capital

MeasurePFEIndustry medianIndustry percentileSector median
ROE (on average equity) 5.0% 24.0%
20th		 0.8%
ROA 2.1% 6.9%
18th		 -0.3%
ROIC 12.1% 15.9%
36th		 5.5%
ROCE 4.1% 15.6%
18th		 2.3%
Return on tangible assets 3.4% 11.2%
9th		 1.7%
Cash ROIC (OCF / invested capital) 9.8% 22.4%
9th		 9.7%
Gross profitability (GP / assets) 22.6% 34.0%
9th		 29.9%
ROIC, 3-yr average 5.9% 10.3%
36th		 2.6%
ROIC, 5-yr average 12.1% 14.2%
44th		 3.2%
ROE, 5-yr average 13.9% 19.6%
33rd		 -4.9%
Incremental ROIC -257.4% 4.4%
9th		 17.2%

Growth

MeasurePFEIndustry medianIndustry percentileSector median
Revenue growth (TTM YoY) -0.2% 5.0%
18th		 10.5%
Revenue growth (QoQ) 4.0% 8.6%
18th		 7.2%
Revenue CAGR, 3 yr -6.7% 4.4%
0th		 10.7%
Revenue CAGR, 5 yr 2.9% 3.3%
45th		 12.1%
Gross profit CAGR, 3 yr -3.1% 5.9%
18th		 10.6%
Operating income CAGR, 3 yr -12.8% 10.0%
10th		 11.7%
Net income growth (TTM YoY) -59.7% -6.6%
20th		 17.5%
Net income CAGR, 3 yr -41.4% 3.1%
0th		 11.3%
EPS growth (TTM YoY) -59.6% -4.3%
20th		 19.2%
EPS CAGR, 3 yr -41.3% 2.7%
0th		 14.0%
EPS CAGR, 5 yr -19.8% 2.2%
0th		 8.1%
FCF growth (TTM YoY) -11.7% 4.7%
10th		 18.6%
FCF CAGR, 3 yr 1.0% 11.3%
9th		 15.4%
Operating cash flow CAGR, 3 yr -2.7% 6.8%
9th		 11.9%
Book value CAGR, 3 yr -4.8% 5.2%
22nd		 2.1%
Dividend CAGR, 3 yr 0.6% 1.8%
10th		 2.2%
Sustainable growth rate -6.3% 11.0%
11th		 12.2%

Margin history & stability

MeasurePFEIndustry medianIndustry percentileSector median
Gross margin, 3-yr average 62.6% 70.1%
9th		 62.6%
Operating margin, 3-yr average 19.5% 23.5%
18th		 1.0%
Net margin, 3-yr average 6.3% 13.4%
18th		 -2.6%
FCF margin, 3-yr average 15.1% 22.0%
18th		 3.2%
Revenue stability (0-1) 0.02 0.75
0th		 0.80
Earnings stability (0-1) 0.33 0.23
64th		 0.37
Margin stability (0-1) 0.87 0.94
0th		 0.93

Liquidity (latest quarter)

MeasurePFEIndustry medianIndustry percentileSector median
Cash & short-term investments $11.7B $7.4B
82nd		 $330.9M
Net cash (− = net debt) −$51.5B −$36.7B
9th		 $8.4M
Working capital $8.7B $4.1B
64th		 $381.1M
Current ratio 1.27 1.29
45th		 3.02
Quick ratio 0.96 1.05
36th		 2.51
Cash ratio (cash + ST investments / current liabilities) 0.36 0.31
64th		 1.43
Defensive interval (days) 300 days 287 days
55th		 415 days

Leverage & solvency (latest quarter)

MeasurePFEIndustry medianIndustry percentileSector median
Total debt $63.2B $49.0B
91st		 $289.1M
Debt / equity 0.74 1.29
30th		 0.45
Net debt / equity 0.60 1.12
30th		 −0.13
Debt / assets 31.4% 40.8%
27th		 24.4%
Debt / capital 42.6% 56.2%
30th		 31.1%
Debt / EBITDA 4.84 3.30
82nd		 2.62
Net debt / EBITDA 3.94 2.75
82nd		 1.42
Interest coverage (EBIT / interest) 2.6x 5.3x
18th		 2.1x
Cash interest coverage 5.0x 9.8x
18th		 3.6x
Debt payback (years of OCF) 4.7 yrs 2.8 yrs
91st		 2.7 yrs
Liabilities / assets 57.5% 71.1%
18th		 49.8%
IS credit model rating BB — —
Implied credit spread (bps) 475 250
73rd		 225

Efficiency

MeasurePFEIndustry medianIndustry percentileSector median
Asset turnover 0.31 0.49
0th		 0.56
Fixed asset turnover 3.35 4.31
27th		 4.87
Inventory turnover 1.7 2.1
36th		 2.7
Receivables turnover 5.2 4.9
64th		 6.4
Days sales outstanding 70 days 74 days
36th		 57 days
Days inventory outstanding 216 days 172 days
64th		 136 days
Days payables outstanding 97 days 116 days
27th		 59 days
Cash conversion cycle (days) 189 days 126 days
82nd		 70 days
Capex / revenue 3.8% 4.6%
30th		 2.6%
Capex / depreciation 0.39 0.49
20th		 0.55
Operating expense ratio 41.5% 40.9%
55th		 56.5%

Cash flow & earnings quality

MeasurePFEIndustry medianIndustry percentileSector median
Operating cash flow / net income 3.09 1.44
70th		 1.61
FCF / net income 2.53 1.24
70th		 1.36
FCF / operating cash flow 82.0% 81.5%
60th		 81.2%
Capex / operating cash flow 18.0% 18.5%
40th		 18.8%
Accruals ratio -4.5% -4.3%
45th		 -5.4%
Sloan accruals ratio -1.7% -2.6%
55th		 -1.3%
Earnings quality score (0-1) 1.00 1.00
30th		 0.75

Dividends & buybacks

MeasurePFEIndustry medianIndustry percentileSector median
Dividend yield 5.8% 2.2%
100th		 0.0%
Dividend per share (TTM) $1.72 $3.33
18th		 $0.00
Payout ratio (dividends / net income) 225.7% 60.0%
90th		 0.0%
Dividends / FCF 89.1% 50.8%
100th		 0.0%
Dividend growth (YoY) 1.6% 5.0%
10th		 4.5%
Buyback yield 0.0% 0.1%
0th		 0.0%
Shareholder yield (dividends + buybacks) 5.8% 2.5%
100th		 0.0%
Share count change (YoY) -0.1% -0.1%
45th		 2.0%
Buybacks, last 5 years $0 $3.6B
0th		 $0

Scores & forensic checks

MeasurePFEIndustry medianIndustry percentileSector median
IS score 46 64
18th		 46
IS profitability 45 67
27th		 22
IS growth 20 40
9th		 60
IS value 49 42
82nd		 39
IS momentum 55 67
27th		 67
IS risk (safety) 50 72
9th		 80
IS quality 73 72
55th		 49
IS balance sheet 43 49
36th		 55
IS earnings quality 71 68
82nd		 56
IS cash flow 59 66
9th		 41
Piotroski F-score (0-9) 7 7
45th		 5
Altman Z-score 2.0 3.0
9th		 3.2
Beneish M-score −2.72 −2.72
45th		 −2.62
Ohlson O-score −8.49 −8.11
27th		 −7.16
IS credit score 43 60
18th		 62

Per share

MeasurePFEIndustry medianIndustry percentileSector median
EPS, diluted (TTM) $0.76 $5.07
9th		 −$0.03
Book value per share $14.95 $19.22
36th		 $7.10
Tangible book per share −$5.79 −$8.38
64th		 $1.91
Revenue per share $11.18 $32.71
0th		 $9.38
FCF per share $1.93 $7.97
9th		 $0.46
Operating cash flow per share $2.35 $9.66
0th		 $0.93
Cash per share $2.05 $4.10
0th		 $3.51

Size (TTM)

MeasurePFEIndustry medianIndustry percentileSector median
Market cap $168.6B $245.2B
27th		 $2.4B
Revenue $63.7B $58.5B
64th		 $770.2M
EBITDA $13.1B $16.9B
27th		 $56.1M
Net income $4.3B $7.5B
36th		 −$3.3M
Free cash flow $11.0B $12.3B
36th		 $41.2M
Total assets $201.1B $118.9B
100th		 $1.3B
Shareholders' equity $85.2B $28.1B
100th		 $568.4M
Employees 75,000 53,500
73rd		 1,086

Insider transactions, last 6 months

Form 4 · most recent 12
DateInsiderTypeSharesPriceValueOwned after
2026-10-15Bourla Albert
Director, Chairman & CEO
 Award / grant 20——783,997
2026-10-13Bourla Albert
Director, Chairman & CEO
 Award / grant 71——783,981
2026-09-30Bourla Albert
Director, Chairman & CEO
 Award / grant 21——783,888
2026-09-25Buckley Mortimer J
Director
 Award / grant 1,308——28,040
2026-09-25Echevarria Joseph
Director
 Award / grant 1,613——169,739
2026-09-25Narayen Shantanu
Director
 Award / grant 1,744——205,649
2026-09-25Quincey James
Director
 Award / grant 1,352——90,671
2026-09-25Smith James C
Director
 Award / grant 1,570——187,210
2026-09-25Taraporevala Cyrus
Director
 Award / grant 1,308——38,806
2026-09-15Bourla Albert
Director, Chairman & CEO
 Award / grant 22——783,985
2026-08-31Bourla Albert
Director, Chairman & CEO
 Award / grant 21——784,012
2026-08-28Guegan Cecile
Executive Vice President
 — 33,051$25.75$851,0630

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types
MarAprMayJunJulAugSepOct

By transaction type, 6 months

TypeDirectionFilingsSharesValue
Award / grantAcquired37104,370—
Open-market buyAcquired3114,863$3.0M
Open-market saleDisposed25,278$134,661
—Disposed895,997$2.9M
Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

FiledFilerShares proposedEst. proceeds
2025-05-23Dolsten Mikael59,781$1.4M
2025-05-05Dolsten Mikael55,000$1.3M
2023-09-13Pao William54,379$1.9M
A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 18 trades (8 purchases) · Senate 4 (2 purchases)
TradedMemberChamberTypeAmountDisclosed
2026-09-25Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-09-11Ro KhannaHousePurchase$1,001 - $15,0002026-10-09
2026-09-04Ro KhannaHouseSale$15,001 - $50,0002026-10-09
2026-07-07Ro KhannaHousePurchase$1,001 - $15,0002026-08-12
2026-06-08Tommy TubervilleSenateSale$15,001 - $50,0002026-07-16
2026-06-08Thomas Hawley TubervilleSenateSale$15,001 - $50,0002026-07-16
2026-02-03Susan M. CollinsSenatePurchase$15,001 - $50,0002026-03-25
2026-02-03Susan Margaret CollinsSenatePurchase$15,001 - $50,0002026-03-25
STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed
ManagerSharesValue% of shares out
BlackRock, Inc.529,670,433$12.8B9.29%
VANGUARD CAPITAL MANAGEMENT LLC372,149,852$9.0B6.53%
STATE STREET CORP307,090,897$7.4B5.39%
GEODE CAPITAL MANAGEMENT, LLC135,275,782$3.2B2.37%
VANGUARD PORTFOLIO MANAGEMENT LLC119,235,030$2.9B2.09%
Fisher Asset Management, LLC109,067,291$2.6B1.91%
MORGAN STANLEY76,408,890$1.8B1.34%
NORGES BANK61,505,586$1.5B1.08%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/56,551,011$1.4B0.99%
Bank of New York Mellon Corp55,715,442$1.3B0.98%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO54,508,560$1.3B0.96%
GOLDMAN SACHS GROUP INC52,991,850$1.3B0.93%
Sixth Street Partners Management Company, L.P.52,060,138$1.3B0.91%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC52,060,138$1.3B0.91%
NORTHERN TRUST CORP45,488,781$1.1B0.80%

Institutional ownership by quarter

2023-092026-0667.8%
% of shares held by 13F filers
2023-092026-062,849
Number of 13F filers holding

Holder changes by quarter

QuarterHoldersOwnershipNewIncreasedReducedClosed
2026-06-302,84967.8%1531,1671,227233
2026-03-312,96866.0%2571,3111,090165
2025-12-312,92765.5%3351,0801,271165
2025-09-302,82463.7%2071,1211,224153
2025-06-302,82265.5%1421,1801,239230
2025-03-312,94766.0%1851,2901,201190
2024-12-313,00965.9%3849361,471245
2024-09-302,92266.1%1951,2441,204130
2024-06-302,89065.7%2161,1871,246173
2024-03-312,89066.7%1931,2301,250214
2023-12-312,95268.0%3328701,595268
2023-09-302,94068.6%1291,1941,386201

Schedule 13D / 13G filers

FiledFormFiler% of classShares
2026-05-01SCHEDULE 13GVanguard Capital Management7.5%427,444,872
2026-03-27SCHEDULE 13G/AThe Vanguard Group0.0%0
Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETFWeight in fundHolding value
VITSX0.22%$5.2B
VTI0.22%$5.2B
VSMPX0.22%$5.2B
VTSAX0.22%$5.2B
VFINX0.25%$4.3B
VFIAX0.25%$4.3B

Share structure

Shares outstanding5,699,670,000
Float5,692,036,026
Free float99.9%

Income statement

Fiscal years, USD
FY2021FY2022FY2023FY2024FY2025
Revenue$81.3B$100.3B$59.6B$63.6B$62.6B
Cost of revenue$34.4B$38.2B$29.2B$21.8B$18.6B
Gross profit$46.9B$62.1B$30.3B$41.8B$44.0B
R&D$13.8B$11.4B$10.6B$10.7B$12.0B
SG&A$12.3B$13.1B$14.5B$14.7B$13.3B
Operating income$20.8B$37.5B$5.3B$16.5B$15.4B
EBITDA$30.8B$41.0B$9.6B$18.1B$15.1B
Pretax income$24.3B$34.7B$1.1B$8.0B$7.5B
Income tax$1.9B$3.3B−$1.1B−$28.0M−$266.0M
Net income$22.1B$31.4B$2.1B$8.0B$7.8B
EPS, diluted$3.88$5.47$0.37$1.41$1.36
Diluted shares5.7B5.7B5.7B5.7B5.7B

Balance sheet

FY2021FY2022FY2023FY2024FY2025
Cash & short-term investments$31.1B$22.7B$12.7B$20.5B$13.6B
Receivables$15.7B$14.5B$15.5B$14.8B$11.9B
Inventory$9.1B$9.0B$10.2B$10.9B$10.7B
Total current assets$59.7B$51.3B$43.3B$50.4B$42.9B
PP&E, net$14.9B$16.3B$18.9B$18.4B$21.5B
Goodwill & intangibles$74.4B$94.7B$132.7B$123.9B$125.0B
Total assets$181.5B$197.2B$226.5B$213.4B$208.2B
Accounts payable$5.6B$6.8B$6.7B$5.6B$5.2B
Total current liabilities$42.7B$42.1B$47.8B$43.0B$37.0B
Long-term debt$34.8B$31.9B$60.5B$57.4B$61.6B
Total liabilities$104.0B$101.3B$137.2B$124.9B$121.4B
Shareholders' equity$77.5B$95.9B$89.3B$88.5B$86.8B

Cash flow statement

Outflows are negative
FY2021FY2022FY2023FY2024FY2025
Net income$22.5B$31.4B$2.2B$8.1B$7.7B
Depreciation & amortization$5.2B$5.1B$6.3B$7.0B$6.6B
Stock-based compensation$1.2B$872.0M$525.0M$877.0M$0
Change in working capital$12.8B−$4.5B−$2.2B−$3.1B−$5.4B
Operating cash flow$32.6B$29.3B$8.7B$12.7B$11.7B
Capital expenditure−$2.7B−$3.2B−$3.9B−$2.9B−$2.6B
Free cash flow$29.9B$26.0B$4.8B$9.8B$9.1B
Investing cash flow−$22.5B−$15.8B−$32.3B$2.7B−$1.4B
Net debt issued / repaid−$1.1B−$3.5B$35.9B−$7.2B−$74.0M
Buybacks$0−$2.0B$0$0$0
Dividends paid−$8.7B−$9.0B−$9.2B−$9.5B−$9.8B

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end
FY2021FY2022FY2023FY2024FY2025
Gross margin57.7%62.4%50.1%66.8%70.3%
Operating margin26.9%37.9%8.0%26.9%24.7%
Net margin27.3%31.3%3.6%12.6%12.4%
FCF margin36.7%25.9%8.0%15.5%14.5%
ROE31.7%36.3%2.3%9.1%8.9%
ROIC24.3%31.9%6.6%12.8%11.4%
ROA13.2%16.6%1.0%3.6%3.7%
Debt / equity0.480.360.800.760.78
Interest coverage19.8x29.0x1.5x4.4x3.8x
Current ratio1.401.220.911.171.16
Revenue growth+94.2%+23.4%−40.6%+6.8%−1.6%
EPS growth+138.2%+41.7%−93.1%+272.1%−2.8%
P/E at year end12.5x7.9x66.9x17.6x18.2x
EV / EBITDA at year end9.2x6.3x21.0x9.0x11.6x
FCF yield at year end10.77%10.52%3.35%6.97%6.41%
Dividend payout39.3%28.6%433.3%118.6%125.8%

Revenue by segment

FY2021FY2022FY2023FY2024FY2025
Biopharma Segment$79.6B$99.0B$57.2B$62.4B$61.2B
Segment Reporting, Reconciling Item, Corporate Nonsegment————$1.4B
Business Innovation Segment——$1.3B——

Revenue by region · FY2025

UNITED STATES$37.1B · 59%
Developed Rest Of World$16.2B · 26%
Emerging Markets$9.3B · 15%

Street estimates by fiscal year

Next report 2026-11-03 · consensus EPS $0.73 · these are analysts' numbers, not ours
Fiscal yearRevenue (mean)Revenue rangeEPS (mean)EPS rangeAnalystsP/E on mean EPS
2026$62.2B$61.3B – $63.0B$2.96$2.89 – $3.031410.0x
2027$59.8B$58.2B – $61.1B$2.90$2.79 – $3.101310.2x
2028$54.8B$50.9B – $58.1B$2.49$1.61 – $3.03811.9x

Reported vs expected, every quarter on file

ReportedEPS expectedEPS actualEPS surpriseRevenue expectedRevenue actualRevenue surprise
2026-08-04$0.68$0.77+12.9%$14.4B$15.0B+4.4%
2026-05-05$0.72$0.75+3.9%$13.8B$14.5B+4.4%
2026-02-03$0.57$0.66+16.4%$16.8B$17.6B+4.2%
2025-11-04$0.63$0.87+37.4%$16.5B$16.7B+0.9%
2025-08-05$0.58$0.78+34.5%$13.6B$14.7B+8.1%
2025-04-29$0.67$0.92+38.1%$13.9B$13.7B−1.5%
2025-02-04$0.47$0.63+33.6%$17.4B$17.8B+2.4%
2024-10-29$0.61$1.06+72.6%$14.9B$17.7B+18.6%
2024-07-30$0.46$0.60+31.0%$13.0B$13.3B+2.5%
2024-05-01$0.52$0.82+58.9%$13.9B$14.9B+7.2%
2024-01-30$-0.19$0.10+152.6%$14.2B$14.2B+0.0%
2023-10-31$-0.32$-0.17+46.9%$12.7B$13.2B+4.0%
2023-08-01$0.56$0.67+19.6%$12.1B$12.7B+5.4%
2023-05-02$0.98$1.23+25.5%$16.6B$18.3B+10.2%
2023-01-31$1.05$1.14+8.6%$24.4B$24.3B−0.4%
2022-11-01$1.39$1.78+28.1%$21.1B$22.6B+7.4%
2022-07-28$1.78$2.04+14.6%$25.5B$27.7B+8.8%
2022-05-03$1.47$1.67+13.6%$24.1B$25.7B+6.5%
2022-02-08$0.85$1.08+27.1%$24.2B$23.8B−1.3%
2021-11-02$1.09$1.34+22.9%$22.4B$24.1B+7.7%
2021-07-28$0.97$1.07+10.3%$22.9B$19.0B−17.0%
2021-05-04$0.77$0.93+20.8%$13.6B$14.6B+7.6%
2021-02-02$0.46$0.42−8.7%$6.7B$11.7B+74.6%
2020-10-27$0.70$0.72+2.9%$12.0B$12.1B+1.4%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)
0.706-151.206-220.706-290.707-060.707-130.507-200.907-271.008-030.808-100.808-170.708-240.808-31
Week ofNotionalSharesTrades
2026-08-31$757.8M26,452,676180,186
2026-08-24$650.8M23,102,903154,494
2026-08-17$835.6M30,042,726188,624
2026-08-10$825.1M30,901,483199,815
2026-08-03$1.0B40,546,575227,322
2026-07-27$863.2M34,548,796206,507

Short-sale share of off-exchange volume

daily 20-day average
07-2310-1542.8%
DateShort shareShort volumeTotal volume
2026-10-1542.8%5,581,61513,032,302
2026-10-1443.8%7,522,96017,188,454
2026-10-1356.0%5,576,4369,963,901
2026-10-1264.3%4,787,7627,443,999
2026-10-0943.7%4,201,0479,624,083
2026-10-0845.9%5,364,81311,677,641
2026-10-0746.5%5,083,73610,922,819
2026-10-0646.7%5,227,26711,196,513
2026-10-0554.6%7,177,60613,155,975
2026-10-0249.4%7,564,35815,298,445
A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month
-2.2Jan-2.2Feb+1.5Mar+0.5Apr+1.0May-1.1Jun+2.6Jul+0.1Aug-0.2Sep-0.0Oct+3.5Nov+0.5Dec
MonthAvg returnUp yearsYears
Jan−2.2%30%20
Feb−2.2%35%20
Mar+1.5%52%21
Apr+0.5%45%20
May+1.0%50%20
Jun−1.1%50%20
Jul+2.6%60%20
Aug+0.1%55%20
Sep−0.2%55%20
Oct−0.0%45%20
Nov+3.5%80%20
Dec+0.5%40%20
History, not a forecast.

Indicators

as of 2026-10-16
RSI 1469.7
MFI53.2
ADX23.2
Stochastic %K / %D87.0 / 80.9
Williams %R-11.2
CCI177
TSI / signal20.5 / 13.3
Chaikin money flow0.13
ATR$0.55
Bollinger width8.2%
Volume vs 20-day avg0.75x
SupertrendUp

Moving averages and bands

level (price vs level)
SMA 20$28.34 (+4.4%)
SMA 50$27.97 (+5.8%)
SMA 200$26.50 (+11.6%)
EMA 21$28.39 (+4.2%)
EMA 50$27.77 (+6.5%)
EMA 200$26.47 (+11.7%)
Bollinger upper$29.50 (+0.3%)
Bollinger lower$27.18 (+8.8%)
Parabolic SAR$27.40 (+8.0%)
Open the live chart, 110+ indicators

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

https://www.pfizer.com

Key executives

NameTitlePayBorn
Albert BourlaChairman of the Board & Chief Executive Officer$9.1M1962
Chris Boshoff FMedSciChief Scientific Officer and President of Research & Development$5.2M1964
Aamir MalikExecutive Vice President & Chief U.S. Commercial Officer$4.9M1976
Douglas LanklerExecutive Vice President & Chief Legal Officer$4.6M1966
Cecile GueganInterim CFO & Executive VP—1971
Dennis HancockExecutive VP & Chief Information Officer——
Francesca DeMartinoChief Investor Relations Officer——
Jennifer DamicoSenior Vice President, Controller & Principal Accounting Officer—1969

Executive pay, latest proxy

ExecutiveYearSalaryStock awardsIncentiveTotal
A. Bourla Chairman and Chief Executive Officer2025$1.8M$9.4M$5.4M$27.6M
C. Boshoff Chief Scientific Officer and President, Research & Development2025$1.4M$1.8M$3.1M$10.0M
D. Denton Chief Financial Officer, EVP2025$1.4M$2.4M$2.8M$9.7M
A. Malik Chief U.S. Commercial Officer, EVP2025$1.4M$2.3M$2.9M$9.4M
D. Lankler Chief Legal Officer, EVP2025$1.4M$2.0M$2.7M$9.1M

Employees

92k201888k201978k202079k202183k202288k202381k202475k2025

Dividends

Ex-dateAmountPaid
2026-11-06$0.432026-12-07
2026-07-24$0.432026-09-01
2026-05-08$0.432026-06-12
2026-01-23$0.432026-03-06
2025-11-07$0.432025-12-01
2025-07-25$0.432025-09-02
2025-05-09$0.432025-06-13
2025-01-24$0.432025-03-07

Moat model

Narrow · Efficient Scale · 2026-06-28
Cost advantage60
Intangibles82
Switching costs34
Network effect45
Efficient scale85
Our component scores (0-100) and overall 60.5; a model of the business, not a call on the stock.
InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms